Oral immune regulation: A new mode of therapy against chronic viral infections

Recent Patents on Anti-Infective Drug Discovery

Volumn 2, Issue 3, 2007, Pages 217-221

  Levy, Liran ^a   Ilan, Yaron ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Anti viral immunity; Hepatitis B; Hepatitis C; Oral immune regulation; Oral tolerance

Indexed keywords

ALPHA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; LIVER PROTEIN; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ADOPTIVE TRANSFER; ANTIINFLAMMATORY ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INFECTION; INFLAMMATORY DISEASE; LIVER INJURY; LOW DRUG DOSE; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PATENT; PRIORITY JOURNAL; REVIEW; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS PARTICLE;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, VIRAL; CHRONIC DISEASE; HUMANS; IMMUNITY; PATENTS AS TOPIC; T-LYMPHOCYTES, REGULATORY; VIRUS DISEASES;

EID: 36749002869     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489107782497353     Document Type: Review

References (75)

1. Weiner HL, Friedman A, Miller A, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994; 12:809-837.
2. Strobel S, Mowat AM. Immune responses to dietary antigens: oral tolerance. Immunol Today 1998; 19:173-181.
3. Garside P, Mowat AM. Mechanisms of oral tolerance. Crit Rev Immunol 1997;17:119-137.
4. Fowler E, Weiner HL. Oral tolerance: elucidation of mechanisms and application to treatment of autoimmune diseases. Biopolymcrs 1997; 43:323-335.
5. Mowat AM, Parker LA, Beacock-Sharp H, Millington OR, Chirdo F. Oral tolerance: overview and historical perspectives. Ann NY Acad Sci 2004; 1029:1-8.
6. Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 2006; 13:143-157.
7. Rottiers, P., Snocck, V.: W007063075 (2007).
8. Trop S, Samsonov D, Gotsman I, Alper R, Diment J, Ilan Y. Liver-associated lymphocytes expressing NK1.1 arc essential for oral immune tolerance induction in a murine model. Hepatology 1999; 29:746-755.
9. Weiner HL. Current issues in the treatment of human diseases by mucosal tolerance. Ann N Y Acad Sci 2004; 1029:211-224.
10. Faria AM, Weiner HL. Oral tolerance and TGF-β-producing cells. Inflamm Allergy Drug Targets 2006; 5:179-190.
11. Faria AM, Weiner BL. Oral tolerance. Immunol Rev 2005; 206:232-259.
12. Ilan Y, Gotsman I, Pines M, et al. Induction of oral tolerance in splenocyte recipients toward pretransplant antigens ameliorates chronic graft versus host disease in a murinc model. Blood 2000; 95:3613-3619.
13. Elinav E, Pappo O, Sklair-Levy M, et al. Amelioration of non-alcoholic steatohepatitis and glucose intolerance in ob/ob mice by oral immune regulation towards liver-extracted proteins is associated with elevated intrahcpatic NKT lymphocytes and serum IL-10 levels. J Pathol 2006; 208:74-81.
14. Margalit M, Israeli E, Shibolet O, et al. A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach. Am J Gastroenterol 2006; 101: 561-568.
15. Mowat AM. Basic mechanisms and clinical implications of oral tolerance. Curr Opin Gastroenterol 1999; 15: 546-556.
16. Mayer L, So LP, Yio XY, Small G. Antigen trafficking in the intestine. Ann N Y Acad Sci 1996; 778: 28-35.
17. Mayer L, Shao L. Therapeutic potential of oral tolerance. Nat Rev Immunol 2004; 4: 407-419.
18. Mayer L. Mucosal immunity and gastrointestinal antigen processing. J Pediatr Gastroenterol Nutr 2000; 30(Suppl): S4-12.
19. Mayer L, Shao L. The use of oral tolerance in the therapy of chronic inflammatory/autoimmune diseases. J Pediatr Gastroenterol Nutr 2004;39 (Suppl 3): S746-47.
20. Lehner, T., Kelly, C., Wang, Y.: W007054658 (2007).
21. Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2003; 3:331-341.
22. Mayer L. Review article: Local and systemic regulation of mucosal immunity. Aliment Pharmacol Ther 1997; 11 Suppl 3:81-5; discussion 85-88.
23. Kasper, D.I., Mazmanian, S.K.: W007092451 (2007).
24. Garside P, Mowat AM. Oral tolerance. Semin Immunol 2001; 13: 177-185.
25. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001; 182: 207-214.
26. Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997; 18: 335-343.
27. Strobel S. Immunity induced after a feed of antigen during early life: oral tolerance v. sensitisation. Proc Nutr Soc 2001; 60: 437-442.
28. Strobel S. Oral tolerance, systemic immunoregulation, and autoimmunity. Ann N Y Acad Sci 2002; 958: 47-58.
29. Ilan Y. Oral tolerance: a new tool for the treatment of gastrointestinal inflammatory disorders and liver-directed gene therapy. Can J Gastroenterol 1999; 13: 829-835.
30. Ilan Y, Chowdhury JR. Induction of tolerance to hepatitis B virus: can we 'eat the disease' and live with the virus? Med Hypotheses 1999; 52: 505-509.
31. Rekvig OP, Bendiksen S, Moens U. Immunity and autoimmunity induced by polyomaviruses: clinical, experimental and theoretical aspects. Adv Exp Med Biol 2006; 577: 117-147.
32. Bowie AG. Translational mini-review series on Toll-like receptors: recent advances in understanding the role of Toll-like receptors in anti-viral immunity. Clin Exp Inummol 2007; 147: 217-226.
33. Goni F, Knudsen E, Schreiber F, et al. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 2005; 133: 413-421.
34. Margalit M, Ilan Y. Oral immune regulation: a novel method for modulation of anti-viral immunity. J Clin Virol 2004; 31 (Suppl 1): S63-68.
35. Ilan Y, Saito H, Thummala NR, Chowdhury NR. Adenovirus-mediated gene therapy of liver diseases. Semin Liver Dis 1999; 19: 49-59.
36. Ilan Y, Sauter B, Chowdhury NR, et al. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology 1998; 27: 1368-1376.
37. Ilan Y, Prakash R, Davidson A, et al. Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors. J Clin Invest 1997; 99: 1098-1106.
38. Doherty PC, Turner SJ. The virus-immunity ecosystem. Arch Virol Suppl 2005: 17-32.
39. Mcfaddcn, G.: US20060263333 (2006).
40. Visvanathan K, Lewin SR. Immunopathogenesis: role of innate and adaptive immune responses. Semin Liver Dis 2006; 26:104-115.
41. Hui CK, Lau GK. Immune system and hepatitis B virus infection. J Clin Virol 2005; 34(Suppl 1): S44-48.
42. Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 2003; 38: 4-13.
43. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis 2002; 2: 43-50.
44. Webster GJ, Bertoletti A. Control or persistence of hepatitis B virus: the critical role of initial host-virus interactions. Immunol Cell Biol 2002; 80:101-105.
45. Lok AS. Hepatitis B infection: pathogenesis and management. J Hepatol 2000;32:89-97.
46. Rehermann B. Immunopathogenesis of viral hepatitis. Baillieres Clin Gastroenterol 1996; 10:483-500.
47. Chisari FV. Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis. Curr Top Microbiol Immunol 1996; 206:149-173.
48. Gotsman I, Beinart R, Alper R, Rabbani E, Engelhardt D, Ilan Y. Induction of oral tolerance towards hepatitis B envelope antigens in a murine model. Antiviral Res 2000; 48:17-26.
49. Michel ML, Mancini-Bourgine M. Therapeutic vaccination against chronic hepatitis B virus infection. J Clin Virol 2005; 34(Suppl 1): S108-114.
50. Safadi R, Israeli E, Papo O, et al. Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. Am J Gastroenterol 2003; 98:2505-2515.
51. Lloyd AR, Jagger E, Post JJ, et al. Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunol Cell Biol 2007; 85:24-32.
52. Ilan, Y.: US20030170258 (2003).
53. Pavio N, Lai MM. The hepatitis C virus persistence: how to evade the immune system. J Biosci 2003; 28:287-304.
54. Polyak SJ. Hepatitis C virus - cell interactions and their role in pathogenesis. Clin Liver Dis 2003; 7:67-88.
55. Israeli E, Safadi R, Melhem A, et al. Induction of oral immune regulation towards liver-extracted proteins for treatment of chronic HBV and HCV hepatitis: results of a phase I clinical trial. Liver Int 2004; 24:295-307.
56. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007; 25:297-336.
57. Engelmayer, I., Petrak, K., Varadhachary, A.L.: WO07022537 (2007).
58. Nowak M, Stein-Streilein J. Invariant NKT cells and tolerance. Int Rev Immunol 2007; 26:95-119.
59. Ilan, Y.: WO04032463A2 (2004).
60. Stein-Streilein J. A privileged view of NKT cells and peripheral tolerance through the eye. Ocul Immunol Inflamm 2005; 13:111-117.
61. La Cava A, Shi FD. Natural and adaptive immune cell-based therapies in autoimmunity. Curr Med Chem 2006; 13:1557-1566.
62. Lalazar G, Preston S, Zigmond E, Ben Yaacov A, Ilan Y. Glycolipids as immune modulatory tools. Mini Rev Med Chem 2006; 6:1249-1253.
63. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004; 22:817-890.
64. Callery MP, Kamei T, Flye MW. Kupffer cell blockade inhibits induction of tolerance by the portal venous route. Transplantation 1989; 47:1092-1094.
65. Callery MP, Kamei T, Flye MW. The effect of portacaval shent on delayed- hypersensitivity responses following antigen feeding. J Surg Res 1989; 46:391-394.
66. Crispe IN. Hepatic T cells and liver tolerance. Nat Rev Immunol 2003; 3:51-62.
67. Shibolet O, Kalish Y, Klein A, et al. Adoptive transfer of ex vivo immune-programmed NKT lymphocytes alleviates immune-mediated colitis. J Leukoc Biol 2004; 75:76-86.
68. Margalit M, Ilan Y. Induction of immune tolerance: a role for Natural killer T lymphocytes. Liver Int 2005; 25:501-504.
69. Menachem Y, Trop S, Kolker O, et al. Adoptive transfer of NK 1.1+ lymphocytes in immune-mediated colitis: a pro-inflammatory or a tolerizing subgroup of cells. Microbes Infect 2005; 7:825-835.
70. Ishimitsu R, Yajima T, Nishimura H, Kawauchi H, Yoshikai Y. NKT cells are dispensable in the induction of oral tolerance but are indispensable in the abrogation of oral tolerance by prostaglandin E. Eur J Immunol 2003; 33:183-193.
71. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Va1pha14 NKT cells in innate and acquired immune response. Annu Rev Inmounol 2003; 21:483-513.
72. La Cava A, Van Kaer L, Fu Dong S. CD4+CD25+ Tregs and NKT cells: regulators regulating regulators. Trends Immunol 2006; 27:322-327.
73. McSorley SJ, Garside P. Vaccination by inducing oral tolerance. Immunol Today 1999; 20:555-560.
74. Han, Y.: WO05032462A2 (2005).
75. Mahanty S, Ravichandran M, Raman U, Jayaraman K, Kumaraswami V, Nutman TB. Regulation of parasite antigen-driven immune responses by interleukin-10 (IL-10) and IL-12 in lymphatic filariasis. Infect Immun 1997; 65:1742-1747.